Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
Type:
Application
Filed:
March 25, 2013
Publication date:
March 26, 2015
Applicant:
BIONTECH AG
Inventors:
Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
Type:
Application
Filed:
September 25, 2013
Publication date:
May 1, 2014
Applicant:
BioNTech AG
Inventors:
Özlem TÜRECI, Ugur SAHIN, Sandra SCHNEIDER, Gerd HELFTENBEIN, Volker SCHLÜTER, Dirk USENER, Philippe THIEL, Michael KOSLOWSKI